Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses-Reference-Cited by-同舟云学术

Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses

Published:2022-02 Issue:2 Volume:17 Page:239-251
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Gounant Valérie,Ferré Valentine Marie,Soussi Ghassen,Charpentier Charlotte,Flament Héloïse,Fidouh Nadhira,Collin Gilles,Namour Céline,Assoun Sandra,Bizot Alexandra,Brouk Zohra,Vicaut Eric,Teixeira Luis,Descamps Diane,Zalcman Gérard

Funder

AstraZeneca

Roche

Bristol-Myers Squibb

Pfizer

Takeda Pharmaceutical Company

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference50 articles.

1. Risk factors for coronavirus disease 2019 (COVID-19) severity and mortality among solid patients with cancer and impact of the disease on anticancer treatment: a French nationwide cohort study (GCO-002 CACOVID-19);Lièvre;Eur J Cancer,2020